Literature DB >> 2077397

Comparison of augmentation of human natural killer cell cytotoxicity by interferon-alpha subtypes.

A Verhagen1, I R Mackay, M Rowley, M Tymms.   

Abstract

The capacity of 3 interferon-alpha (IFN-alpha) subtypes, alpha 1, alpha 2 and alpha 4, to augment human natural killer cytotoxicity after exposure in vitro was shown to be dose-dependent and to differ according to subtype. With 10(2) IU/ml, the lowest IFN concentration used, stimulation of NK activity by IFN-alpha 2 was consistently and significantly greater than by IFN-alpha 4 or IFN-alpha 1. An IFN-alpha analogue in which arginine and lysine residues 121 and 122 were replaced by 2 leucines was generated by site-directed in vitro mutagenesis of the IFN-alpha 4 gene; at equivalent concentrations of antiviral activity, this analogue was 10-fold less effective in NK stimulation. There was a lack of correlation between NK-stimulatory and other activities of the IFN-alpha subtypes and the mutant, suggesting that different biological activities may be mediated by different regions of the IFN-alpha molecule.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2077397

Source DB:  PubMed          Journal:  Nat Immun Cell Growth Regul        ISSN: 0254-7600


  3 in total

1.  IL-2-mediated augmentation of NK-cell activity and activation antigen expression on NK- and T-cell subsets in patients with metastatic melanoma treated with interferon-alpha and DTIC.

Authors:  Gordana Konjević; Viktor Jović; Vladimir Jurisić; Sinisa Radulović; Svetislav Jelić; Ivan Spuzić
Journal:  Clin Exp Metastasis       Date:  2003       Impact factor: 5.150

2.  The association between CD2+ peripheral blood lymphocyte subsets and the relapse of bladder cancer in prophylactically BCG-treated patients.

Authors:  E Reyes; J Carballido; L Manzano; L Moltó; C Olivier; M Alvarez-Mon
Journal:  Br J Cancer       Date:  1999-03       Impact factor: 7.640

3.  Interferon-alpha subtype 11 activates NK cells and enables control of retroviral infection.

Authors:  Kathrin Gibbert; Jara J Joedicke; Andreas Meryk; Mirko Trilling; Sandra Francois; Janine Duppach; Anke Kraft; Karl S Lang; Ulf Dittmer
Journal:  PLoS Pathog       Date:  2012-08-09       Impact factor: 6.823

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.